Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas
Author
dc.contributor.author
Foss, Francine M.
Author
dc.contributor.author
Horwitz, Steven M.
Author
dc.contributor.author
Civallero, Mónica
Author
dc.contributor.author
Bellei, Mónica
Author
dc.contributor.author
Marcheselli, Luigi
Author
dc.contributor.author
Kim, Won Seog
Author
dc.contributor.author
Cabrera, María E.
Author
dc.contributor.author
Dlouhy, Iván
Author
dc.contributor.author
Nagler, Arnon
Author
dc.contributor.author
Advani, Ranjana H.
Author
dc.contributor.author
Pesce, Emanuela A.
Author
dc.contributor.author
Ko, Young-Hyeh
Author
dc.contributor.author
Montoto, Silvia
Author
dc.contributor.author
Chiattone, Carlos
Author
dc.contributor.author
Moskowitz, Alison
Author
dc.contributor.author
Spina, Michele
Author
dc.contributor.author
Cesaretti, Marina
Author
dc.contributor.author
Biasoli, Irene
Author
dc.contributor.author
Federico, Massimo
Admission date
dc.date.accessioned
2021-02-16T18:08:44Z
Available date
dc.date.available
2021-02-16T18:08:44Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
American Journal of Hematology 2020;95:151–155.
es_ES
Identifier
dc.identifier.other
10.1002/ajh.25674
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/178443
Abstract
dc.description.abstract
The T Cell Project was the largest prospective trial to explore the incidence, treatment patterns, and outcomes for T cell lymphomas. The rare subtypes of T cell lymphomas, including hepatosplenic T cell lymphoma (HSTCL), enteropathy associated T cell lymphoma (EATL), and peripheral gamma delta T cell lymphomas (PGDTCLs) are poorly represented in most studies and there is little data regarding treatment patterns. We report results from 115 patients with hepatosplenic (n = 31), enteropathy associated (n = 65), and PGDTCLs (n = 19). While anthracycline regimens were most commonly used as first line therapy, response rates ranged from 20%-40% and were suboptimal for all groups. Autologous stem cell transplantation was performed as a consolidation in first remission in a small number of patients (33% of HSTCL, 7% of EATL, and 12% of PGDTCL), and four patients with HSTCL underwent allogeneic stem cell transplantation in first remission. The progression free survival at 3 years ranged from 28%-40% for these rare subtypes, and the overall survival at 3 years was most favorable for PGDTCL (70%). These data highlight the need for novel treatment approaches for rare subtypes of T cell lymphomas and for their inclusion in clinical trials.
es_ES
Patrocinador
dc.description.sponsorship
Allos pharmaceuticals
Associazione Angela Serra per la Ricerca sul Cancro
Associazione Italiana per la Ricerca sul Cancro (AIRC)
Fondazione Cassa di Risparmio di Modena
Fondazione Italiana Linfomi
Spectrum Pharmaceuticals
NCI CCSG
P30 CA008748
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas